Compugen (NASDAQ:CGEN - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect Compugen to post earnings of ($0.07) per share and revenue of $3.95 million for the quarter.
Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings data on Monday, May 19th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Compugen had a negative return on equity of 24.51% and a negative net margin of 51.27%. The company had revenue of $2.28 million during the quarter, compared to the consensus estimate of $3.70 million. During the same period last year, the business earned ($0.08) EPS. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Compugen Price Performance
Shares of NASDAQ:CGEN traded up $0.03 during trading on Friday, hitting $1.48. 282,242 shares of the company's stock were exchanged, compared to its average volume of 236,550. Compugen has a 52-week low of $1.13 and a 52-week high of $2.66. The business's 50-day simple moving average is $1.62 and its 200 day simple moving average is $1.69. The company has a market cap of $132.08 million, a price-to-earnings ratio of -9.25 and a beta of 2.61.
Compugen Company Profile
(
Get Free Report)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Featured Stories
Before you consider Compugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.
While Compugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access